Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 627 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Increased protein Clear all
Completed Phase 4 Interventional Results available

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

NCT02487797
View directory record Official record
Conditions
Dystocia
Interventions
Oxytocin, Sodium Chloride 0.9%
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT03143985
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Vactosertib, Pomalidomide
Drug
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 8, 2026, 3:34 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Biological · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 4 Interventional Results available

OnabotulinumtoxinA Bladder Injection Study

NCT03523091
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence, Urinary Frequency/Urgency, Urinary Bladder, Overactive
Interventions
OnabotulinumtoxinA 100Unit Injection
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Open-Label Adalimumab for Ulcerative Colitis Patients

NCT00421642
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 8, 2026, 3:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Columbia Moves Physical Activity

NCT03509129
View directory record Official record
Conditions
Physical Activity
Interventions
TECH (Technology), TECH+COMP (Technology + Competition)
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

NCT00511329
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions
somatropin [rDNA origin] for injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

NCT00392756
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

NCT01543971
View directory record Official record
Conditions
Miscellaneous Peripheral Blood Cell Abnormalities
Interventions
TXA127, Neupogen (filgrastim)
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 8, 2026, 3:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

NCT06961357
View directory record Official record
Conditions
Melanoma
Interventions
Cyclophosphamide, Fludarabine, Interleukin-2, TIL Product
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

NCT04678219
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Dietary Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 1 Interventional

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT05083481
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Versus Intracervical Lidocaine

NCT00816751
View directory record Official record
Conditions
Abortion, Induced, Pain
Interventions
Paracervical block, Intracervical, Buffered Lidocaine, vasopressin, sodium bicarbonate
Procedure · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

NCT00003700
View directory record Official record
Conditions
Leukemia
Interventions
G-CSF, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, Allopurinol
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 1 Interventional

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

NCT04594811
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
Interventions
NT-I7, Nivolumab
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Louisville, Kentucky • Ann Arbor, Michigan • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Sep 8, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

NCT07480109
View directory record Official record
Conditions
Obesity, Women (Between 30 to 60 Years Old)
Interventions
Protein Rich Foods
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

NCT01183494
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, Avastin, Irinotecan
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PrOtein and WEight Loss in teenageRs

NCT02079831
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Energy Restriction, Higher protein, Lower Protein
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
12 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 8, 2026, 3:34 PM EDT
Recruiting Phase 2 Interventional

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081
View directory record Official record
Conditions
Atrial Fibrillation, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 8, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944
View directory record Official record
Conditions
Drug Dependence
Interventions
Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 8, 2026, 3:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

NCT00878592
View directory record Official record
Conditions
Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity, Nonalcoholic Steatohepatitis
Interventions
Dietary and life style modification
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Sep 8, 2026, 3:34 PM EDT